Kintai Therapeutics launches to tackle the interface between the gut, immune system, and brain
Tuesday, April 16, 2019 - 06:30
in Biology & Nature
The startup, founded by Flagship Pioneering, is developing small-molecule drugs aimed at the gut microbiome, gut immune cells, and enteric nervous system